Loading
Physiomics plc Stock: price and insider trades · United Kingdom
No insider purchase over the last 90 days. The latest was filed 14 Jul 2026.
Physiomics plc: what insiders have been doing
Physiomics plc is a listed company. Its insiders report their share dealings to RNS (LSE). 2 insiders have disclosed 2 filings since 18 October 2025.
No insider sold shares on the market over the period. Instead, the filings list 2 purchases totalling €22k, made by 2 insiders. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 2 senior executives. The largest single trade was a purchase of €16k by Mike Whitlow, published on 12 July 2026, equal to 0.57% of the market capitalisation.
In all, 1 purchase was made within 30 days of a purchase by another insider of the company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The latest purchase dates back some time: it was published 95 days ago, on 14 July 2026.
Across the 833 companies tracked on its exchange, the median is 6 filings; at 2 filings, this issuer sits below that mark. Over the whole record (from 2026), the tally stands at 2 purchases and no sales.
Source: insider filings from RNS (LSE). Past trades are no guide to future returns.
Insider Decl.
2
Thresholds
n/a
Buy Volume
€21,691
2 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleIan Bagnall2 buys
Mike Whitlow2 buys
Since the insiders bought
- -18.2%Entry £0.01 · Close at T+30 £0.00
- -19.1%Entry £0.01 · Close at T+30 £0.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,981 of 24,148 companies
6.0
score / 100
Value9
Quality3
FCF yld-26%
Earn yld-19%
EV/EBITDA·
ROE-115%
Gross mgn·
Net mgn-53%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended June 2025 · cache
£0.00
Analyst consensus
Income statement
Revenue£784k
EBITDA-£448.2k-57% margin
Net income-£415.3k-48.1% margin
Valuation
P/Book475.0x
Beta1.03
Balance sheet & cash
Market cap£2.2M
Free Cash Flow-£550.1k
Profitability & ownership
ROE-119.7%
ROA-61.6%
% insiders25.7%
% institutions2.3%
Last declaration on 14 July 2026
Declarations2 total
1,111,111 shares@ £0.00450.21% mcap100.0% of flowLondon Stock ExchangeRNS:22f86329-759a-480a-9a8e-278248dc3b0d
Canonical exit: 8 Oct 2026 (T+90)
3,000,000 shares@ £0.00450.57% mcap100.0% of flowLondon Stock ExchangeISIN GB00BDR6W943RNS:9665081
Canonical exit: 8 Oct 2026 (T+90)
2 of 2 declarations
About Physiomics plc
Physiomics plc is a biotechnology company focused on developing modeling solutions for cancer treatment. It utilizes advanced technologies to optimize therapies and enhance clinical outcomes.
